{"protocolSection":{"identificationModule":{"nctId":"NCT06479356","orgStudyIdInfo":{"id":"JWCAR029-117"},"organization":{"fullName":"Shanghai Ming Ju Biotechnology Co., Ltd.","class":"INDUSTRY"},"briefTitle":"CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma","officialTitle":"An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed or Refractory (R/R) LBCL"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-08-31","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-04-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-24","studyFirstSubmitQcDate":"2024-06-24","studyFirstPostDateStruct":{"date":"2024-06-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-24","lastUpdatePostDateStruct":{"date":"2024-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Shanghai Ming Ju Biotechnology Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.","detailedDescription":"This is an open-label, single-arm study conducted in adult subjects with R/R LBCL in China to evaluate efficacy，safety and pharmacokinetics(PK) of relma-cel.\n\nRelma-cel was approved by the China National Medical Products Administration(NMPA)in September 2021(Acceptance No:CXSS2000036)for the treatment of adult patients with R/R LBCL after second-line or more systemic therapy.The recommended dose is 1×10\\^8 CAR+T cells.The indication for this application is R/R LBCL and the recommended dose is 1×10\\^8 CAR+T cells."},"conditionsModule":{"conditions":["Non-Hodgkin Lymphoma","Large B-cell Lymphoma"],"keywords":["JWCAR029","B-Cell Malignancies","CAR T cells","Chimeric antigen receptor","Relapsed/Refractory"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":12,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Relma-cel","type":"EXPERIMENTAL","description":"Efficacy, safety and PK of Relma-cel will be evaluated in 1 x 10\\^8 CAR+T cells dose level","interventionNames":["Biological: Relma-cel"]}],"interventions":[{"type":"BIOLOGICAL","name":"Relma-cel","description":"Relma-cel will be administered at one dose level:1×10\\^8 CAR+T cells","armGroupLabels":["Relma-cel"],"otherNames":["CD19-targeted Chimeric Antigen Receptor(CAR) T Cells"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective response rate (ORR) in LBCL subjects","description":"Objective response rate (ORR) in 3 month evaluated by investigator of LBCL subjects","timeFrame":"3 months"}],"secondaryOutcomes":[{"measure":"Objective response rate (ORR)","description":"Objective response rate (ORR) in 3 month evaluated by IRC of LBCL subjects","timeFrame":"3 months"},{"measure":"Best objective response rate ( Best ORR) in LBCL subjects","description":"Best objective response rate (ORR) evaluated by the investigator and IRC of LBCL subjects","timeFrame":"up to 1 year after Relma-cel infusion"},{"measure":"Complete response rate (CRR) in LBCL subjects","description":"Complete response rate (CRR) at any time points evaluated by the investigator","timeFrame":"up to 1 year after Relma-cel infusion"},{"measure":"Progression-free survival (PFS)","description":"Progression-free survival","timeFrame":"up to 1 year after Relma-cel infusion"},{"measure":"Overall survival (OS)","description":"Overall survival","timeFrame":"up to 1 year after Relma-cel infusion"},{"measure":"Duration of response (DOR)","description":"Time from first response (PR or CR) to disease progression or death from any cause","timeFrame":"up to 1 year after Relma-cel infusion"},{"measure":"Pharmacokinetic(PK)-Cmax of Relma-cel","description":"Maximum observed concentration of Relma-cel in peripheral blood","timeFrame":"up to 1 year after Relma-cel infusion"},{"measure":"Pharmacokinetic(PK)-Tmax of Relma-cel","description":"Time to maximum concentration of Relma-cel in peripheral blood","timeFrame":"up to 1 year after Relma-cel infusion"},{"measure":"Pharmacokinetic(PK)-AUC of Relma-cel","description":"Area under the concentration vs time curve of Relma-cel","timeFrame":"up to 1 year after Relma-cel infusion"},{"measure":"Adverse events (AEs)","description":"These adverse events would be measured by assessment scale method according to NCI-CTCAE v5.0 classification standard","timeFrame":"up to 1 year after Relma-cel infusion"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. ≥18 years old;\n2. Sign on the informed consent;\n3. Subjects must have histologically confirmed Large B-cell Lymphoma;\n4. Subjects had been treated with anthracyclines and rituximab(or other CD20-targeted antibodies) and had relapsed, failed to respond, or progressed after at least two lines of therapy including autologous hematopoietic stem cell transplantation(auto-HSCT);\n5. Subjects have accessible PET-positive lesion and have measurable CT-positive lesion according to Lugano Classification;\n6. Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1;\n7. Adequate organ function;\n8. Adequate vascular access for leukapheresis procedure;\n9. Subjects who have previously received CD19 targeted therapy must confirm that lymphoma lesions still express CD19;\n10. Women of childbearing potential must agree to use highly effective methods of contraception for 1 year after the last dose of Relma-cel;\n11. Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for 1 year after the last dose of Relma-cel.\n\nExclusion Criteria:\n\n1. Primary CNS lymphoma;\n2. History of another primary malignancy that has not been in remission for at least 2 years;\n3. Subjects has HBV,HCV,HIV or syphilis infection at the time of screening;\n4. Active deep venous thrombosis(DVT)/Pulmonary embolism(PE),or active DVT/PE requires anti-coagulation within 3 months prior to signing the ICF;\n5. Subjects with uncontrolled systemic fungal,bacterial,viral or other infection;\n6. Presence of acute or chronic graft-versus-host disease(GVHD);\n7. History of any serious cardiovascular disease or presence of clinically relevant CNS pathology;\n8. Pregnant or nursing woman;\n9. Subjects using of any chemotherapy,corticosteroid,experiment agents,GVHD therapies,radiation,allo-HSCT or any other therapies for lymphoma must go through a specific wash-out period before leukapheresis;\n10. Uncontrolled conditions or unwillingness or inability to follow the procedures required in the protocol;\n11. Received CAR T-cell or other genetically-modified T-cell therapy previously.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Relma-cel Medical","role":"CONTACT","phone":"+86 21 50464201","email":"JWCAR029Medical@jwtherapeutics.com"}],"overallOfficials":[{"name":"Huilai Zhang","affiliation":"Tianjin Cancer Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Tianjin Cancer Hospital","city":"Tianjin","state":"Tianjin","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000008223","term":"Lymphoma"},{"id":"D000016393","term":"Lymphoma, B-Cell"}],"ancestors":[{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000008232","term":"Lymphoproliferative Disorders"},{"id":"D000008206","term":"Lymphatic Diseases"},{"id":"D000007160","term":"Immunoproliferative Disorders"},{"id":"D000007154","term":"Immune System Diseases"},{"id":"D000008228","term":"Lymphoma, Non-Hodgkin"}],"browseLeaves":[{"id":"M11220","name":"Lymphoma","asFound":"Lymphoma","relevance":"HIGH"},{"id":"M18828","name":"Lymphoma, B-Cell","asFound":"B-cell Lymphoma","relevance":"HIGH"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M11225","name":"Lymphoproliferative Disorders","relevance":"LOW"},{"id":"M11203","name":"Lymphatic Diseases","relevance":"LOW"},{"id":"M10206","name":"Immunoproliferative Disorders","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"},{"id":"M11222","name":"Lymphoma, Non-Hodgkin","relevance":"LOW"},{"id":"T3543","name":"Lymphosarcoma","asFound":"Lymphoma","relevance":"HIGH"},{"id":"T640","name":"B-cell Lymphoma","asFound":"B-cell Lymphoma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}